Kết quả tìm kiếm - Hua‐Jun Chen

  • Đang hiển thị 1 - 15 kết quả của 15
Tinh chỉnh kết quả
  1. 1
    Aberrant functional connectivity of default-mode network in type 2 diabetes patients

    Aberrant functional connectivity of default-mode network in type 2 diabetes patients Bằng Ying Cui, Yun Jiao, Hua‐Jun Chen, Jie Ding, Bing Luo, Cheng-Yu Peng, Shenghong Ju, Gao‐Jun Teng

    Được phát hành 2015
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

    Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib Bằng Jin‐Hyoung Kang, Hua‐Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi‐Long Wu, Jin‐Ji Yang

    Được phát hành 2017
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Association of glymphatic system disturbance with neural dysfunction in amyotrophic lateral sclerosis

    Association of glymphatic system disturbance with neural dysfunction in amyotrophic lateral sclerosis Bằng Nao‐Xin Huang, J. Y. Zeng, Hui‐Wei Huang, S.H. Fang, Sheng Chen, Jianqi Li, Hua‐Jun Chen, Zhang‐Yu Zou

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis

    Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis Bằng Fang Nie, Jian Yang, Song Wen, Yanli An, Jie Ding, Shenghong Ju, Zhen Zhao, Hua‐Jun Chen, Xin‐Gui Peng, Stephen T.C. Wong, Hong Zhao, Gao‐Jun Teng

    Được phát hành 2012
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial Bằng Qing Zhou, Jin‐Ji Yang, Zhihong Chen, Xu‐Chao Zhang, Hong‐Hong Yan, Chong‐Rui Xu, Jian Su, Hua‐Jun Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas Bằng Zhiyong Chen, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Xue-Ning Yang, Zhi Hong Chen, Jin-Ji Yang, Qing Zhou, Hong-Hong Yan, She-Juan An, Hua-Jun Chen, Ben‐Yuan Jiang, Tony Mok, Yi‐Long Wu

    Được phát hành 2012
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Distribution and prognosis of uncommon metastases from non-small cell lung cancer

    Distribution and prognosis of uncommon metastases from non-small cell lung cancer Bằng Feiyu Niu, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Zhihong Chen, Wei Deng, Yanyan He, Hua‐Jun Chen, Zhu Zeng, E‐E Ke, Ning Zhao, Na Zhang, Huiwen Sun, Qiuyi Zhang, Zhi Xie, Xu‐Chao Zhang, Yi‐Long Wu

    Được phát hành 2016
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival

    A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival Bằng Chanyuan Zhang, Hao Sun, Junwei Su, Yuqing Chen, Shiling Zhang, Ming-Ying Zheng, Yufa Li, Jie Huang, Chao Zhang, Zaixian Tai, Miao Cai, Xuchao Zhang, Jian Su, Chong‐Rui Xu, Hong‐Hong Yan, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang

    Được phát hành 2022
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer Bằng Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Qing Zhou, Jian Su, Zhen Wang, Chong‐Rui Xu, Yi-Sheng Huang, Bin-Chao Wang, Xue‐Ning Yang, Wen‐Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Ben‐Yuan Jiang, Song Dong, Yi‐Long Wu

    Được phát hành 2012
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Lung Cancers with Concomitant <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

    Lung Cancers with Concomitant <i>EGFR</i> Mutations and <i>ALK</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation Bằng Jin-Ji Yang, Xu‐Chao Zhang, Jian Su, Chong‐Rui Xu, Qing Zhou, Hong-Xia Tian, Zhi Xie, Hua-Jun Chen, Yi-Sheng Huang, Ben‐Yuan Jiang, Zhen Wang, Bin-Chao Wang, Xue-Ning Yang, Wen‐Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Tony Mok, Yi‐Long Wu

    Được phát hành 2014
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

    Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study Bằng Hanmin Wang, Chan-Yuan Zhang, Kai‐Cheng Peng, Ze-Xin Chen, Junwei Su, Yufa Li, Wenfeng Li, Qing-Yun Gao, Shiling Zhang, Yuqing Chen, Qing Zhou, Cong Xu, Chong‐Rui Xu, Zhen Wang, Jian Su, Hong‐Hong Yan, Xu‐Chao Zhang, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang

    Được phát hành 2023
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC

    Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC Bằng Mei-Mei Zheng, Yang-Si Li, Ben‐Yuan Jiang, Hai‐Yan Tu, Wen‐Fang Tang, Jin‐Ji Yang, Xuchao Zhang, Junyi Ye, Hong‐Hong Yan, Jian Su, Qing Zhou, Wen‐Zhao Zhong, Xue‐Ning Yang, Wei‐Bang Guo, Shannon Chuai, Zhou Zhang, Hua‐Jun Chen, Zhen Wang, Chao Liu, Yi‐Long Wu

    Được phát hành 2019
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

    Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study Bằng Chang Lu, Xiaorong Dong, Jun Zhao, Xu‐Chao Zhang, Hua‐Jun Chen, Qing Zhou, Hai‐Yan Tu, Xinghao Ai, Xiaofeng Chen, Gaili An, Jun Bai, Jinlu Shan, Yina Wang, Shuanying Yang, Xiang Liu, Wu Zhuang, Hui-Ta Wu, Bo Zhu, Xuefeng Xia, Rongrong Chen, Dejian Gu, Huamin Xu, Yi‐Long Wu, Jin‐Ji Yang

    Được phát hành 2020
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

    Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma Bằng Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu

    Được phát hành 2016
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

    PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901... Bằng Si‐Yang Maggie Liu, Jie Huang, Jia‐Yi Deng, Chong‐Rui Xu, Hong‐Hong Yan, Mingyi Yang, Yang-Si Li, E‐E Ke, Ming-Ying Zheng, Zhen Wang, Jiaxin Lin, Bin Gan, Xu‐Chao Zhang, Hua‐Jun Chen, Bin-Chao Wang, Hai‐Yan Tu, Jin‐Ji Yang, Wen‐Zhao Zhong, Yangqiu Li, Qing Zhou, Yi‐Long Wu

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: